Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell (GRASP)
NCT05353647Phase 2Active, not recruiting
- Sponsor
- David Williams
- Start
- Jul 2022
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in sickle cell disease (SCD), sponsored by David Williams. Primary endpoint: Occurrence of Vaso-Occlusive Events at 24 months. Started Jul 2022; status: active, not recruiting.
02
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05353647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05353647.